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Abstract 
By analogy to the structural diversity of covalent bond networks between atoms within organic 
molecules, one can design topologically diverse peptides from mathematical graphs by assigning 
amino acids to graph nodes and peptide bonds to graph edges. The key is to use diamino acids or 
amino diacids as equivalents of trivalent graph nodes, which enables a variety of graph 
topologies beyond the standard linear and monocyclic graphs in natural peptides. Here the 
bicyclic decapeptide A1FGk2VFPE1AG2 (1b) was prepared and crystallized to assign its bridge 
stereochemistry. The bridge configuration appears as planned by the chirality of the branching 
amino acids. Bicyclization furthermore depends on the presence of matched chiralities in the 
branching amino acids. The stereoselective formation of the second bridge opens the way for the 
synthesis of a large family of bicyclic peptides as promising new scaffolds for drug design. 
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Introduction 
 
In analogy with the structural diversity of covalent bond networks between atoms within organic 
molecules,1,2 topologically diverse peptides can be designed from mathematical graphs by 
assigning amino acids to graph nodes and peptide bonds to graph edges. The key is to use 
diamino acids (e.g. lysine) or amino diacids (e.g. glutamate) as equivalents of trivalent graph 
nodes, which enables branched peptide chains and therefore a variety of graph topologies beyond 
the standard linear and monocyclic graphs found in naturally occurring peptides and proteins. 
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This graph based strategy opens vast possibilities for molecular design in the size range of MW 
1000-5000 Da, which is usually quite difficult to access by synthesis yet is required for various 
applications where small molecules fail, such as disrupting protein-protein interactions.3,4 
Branched peptide chains are expected to be conformationally constrained or even completely 
rigid, resulting in stronger and more selective target binding and increased resistance to 
proteolytic degradation compared to linear peptides. The use of standard amino acid building 
blocks furthermore ensures relatively low toxicity and unproblematic metabolism, which is one 
key advantage of peptides when considering therapeutic use.5 
Surprisingly, relatively little attention has been paid to a systematic exploration of graph 
based peptide design, except for the preparation of bi- or polycyclic peptides using side chain 
cross-links6 as found in cysteine knot proteins7 and lantibiotics.8 We have shown that peptide 
equivalents of multi-branched graphs can be prepared in good yields and purities by solid phase 
peptide synthesis (SPPS), a robust method to prepare peptides in the laboratory as well as on an 
industrial scale.9 For instance, peptide dendrimers can be obtained in excellent yields by the 
successive use of branching diamino acids producing sequence-symmetrical molecular trees,10 
where multivalency effects enable a variety of properties inaccessible to small molecules such as 
enhancement of organocatalysis,11 remote control of metal coordination properties,12 lectin and 
biofilm inhibition,13 membrane disruptive antimicrobial effects,14 and DNA transfection 
activities.15 
In a similar design, we recently showed that bicyclic peptides comprising two branching 
residues can be produced efficiently by SPPS using a simple orthogonal protection scheme.16 In 
this synthesis, a first peptide cyclization is carried out on the solid support by amide bond 
formation between the N-terminal amino group and the -carboxyl group of a side chain allyl 
ester protected glutamate residue after palladium deprotection. The second cyclization is then 
carried out between the free C-terminal carboxyl group and the -amino group of a Boc protected 
lysine residue after acidic deprotection and simultaneous cleavage from the support (Scheme 1). 
The SPPS of bicyclic peptides gave good results for various combinations such as 
bicyclo[3.3.2]decapeptide 1b, norbornapeptide 2b and bicyclo[2.2.2]octapeptide 3b. In all three 
sequences, one proline residue was included to facilitate on-resin cyclization, while the 
remaining positions were diversified with amino acids carrying non-protected side chains. 
When designing the bicyclic peptides the chirality of the branching diamino acid was 
planned to enable formation of the bridge above or below the plane of the first cycle in a 
stereoselective manner.17 The obtainment of single products after bicyclization indeed strongly 
pointed to a stereoselective process. In the case of the smaller bicyclic peptides such as 2b and 
3b, structure determination by 1H-NMR showed unambiguously that the process was indeed 
stereoselective and that the expected bridge geometry was formed. In the case of the larger 
bicyclo[3.3.2]decapeptide 1b, by constrast, a single product was also observed but the 1H-NMR 
data was inconclusive as to the bridge stereochemistry due to the much smaller number of 
observed NOE-distance constraints, probably caused by the larger and somewhat more flexible 
tripeptide loops. Thus, the issue of which of the two possible bridge stereoisomers, 1b or 1b*, 
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was formed could not be resolved (Figure 1). We therefore set out to test whether the structure 
could be determined by crystallography. Herein we report the structure of 1b, which represents 
one of the few X-ray crystal structures of a homodetic bicyclic peptide.18 The data shows that for 
this larger bicyclic system compared to the norbornapeptides the expected bridge configuration is 
indeed formed, as planned by the chirality of the branching amino acids. The stereoselective 
bridge formation as demonstrated here opens the way for the planned synthesis of a large family 
of conformationally constrained bicyclic peptides, which constitute a promising new class of 
scaffolds for drug design. 
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Scheme 1. Solid-phase synthesis of 1b and graphs of peptides 1-3b. Conditions: a- Fmoc SPPS; 
b- Pd(PPh3)4, PhSiH3, dry CH2Cl2; c- piperidine/DMF 1:4; d- HATU, DIEA, NMP/DMSO 4:1; 
e-TFA/TIS/H2O 94:5:1; f- PyBOP, DIEA, DCM/DMF 10:1. 
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Figure 1. Possible cyclization diastereoisomers and their graph representations. Arrows in the 
structures indicate the direction of the amide bonds. 
 
 
Results and Discussion  
 
Synthesis 
The linear sequence of peptide 1b was first assembled by Fmoc SPPS from commercially 
available building blocks. The sequence was designed to allow the first cyclization between the 
N-terminal alanine residue and the side-chain carboxyl group of the glutamate residue to form 
the larger octapeptide ring. The cyclization was performed on resin using HATU as coupling 
agent. After completion of the reaction as detected by the TNBS test, the resin was treated with 
trifluoroacetic acid, which effected cleavage of the Wang-linker and removal of the lysine side 
chain Boc protecting group. The branched cyclic octapeptide 1a was obtained in 27% yield after 
purification by preparative RP-HPLC. 
The second cyclization to form bicyclic peptide 1b was performed by subjecting the pure 
monocyclic peptide 1a to amide bond formation condition in high dilution (0.7 mM in 
DCM/DMF 8:1), using PyBOP as coupling agent. The reaction proceeded smoothly over 2 h as 
followed by HPLC and gave a single product corresponding to the mass of 1b. The product was 
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isolated in 38% yield after preparative RP-HPLC (Table 1) and its purity was confirmed by 1H-
NMR. 
To test the sensitivity of the second cyclization to the stereochemistry of the branching amino 
acids, the stereoisomeric monocyclic peptide 1a' was prepared bearing an L-lysine branching 
residue at position 7, which would be expected to hamper the formation of the second cycle since 
the stereochemistry of the bridging pair is mismatched. Indeed, while the monocyclic octapeptide 
1a' was obtained in comparable yield as 1a, attempts to form the second cycle from 1a' under the 
same conditions only gave traces of bicyclic product even after prolonged incubation, showing 
that formation of the second peptide ring is subjected to stereochemical constraints. We could 
indeed isolate a peptide with the right mass, but with a complex 1H-NMR spectrum, possibly due 
to the presence of a conformational mixture (Figure S1). 
 
Table 1. Data for the formation of 1a, 1a' and 1b. Superscript 1 and 2 indicate residues 
connected in the 1st and 2nd cyclization, respectively 
No. nr. AA Sequence mg % MS calc. MS obs. 
1a 10 A1FGkVFPE1AG 67.5 27 1004.52 1004.52 
1a' 10 A1FGKVFPE1AG 43.8 17 1004.52 1004.52 
1b 10 A1FGk2VFPE1AG2 22.8 38 986.51 986.51 
 
Crystal structure 
Peptide 1b was subjected to crystallization screening using typical protein crystallization 
conditions (Crystal Screen and Crystal Screen 2, Hampton Research). After screening 98 
different conditions, single crystals suitable for structure determination were obtained with 
Crystal Screen solution 47 (0.1 M sodium acetate trihydrate pH 4.6, 2.0 M ammonium sulfate). 
The presence of two phenylalanines, one valine and one alanine at one face of the peptide 
surface may have facilitated crystallization by limiting solubility in aqueous buffers and has 
yielded extremely well-diffracting rod-shaped crystals. Several X-ray data sets were collected at 
the Swiss Light Source (Paul Scherrer Institute, Villigen) at beamlines X06DA and X06SA. The 
obtained model represents one of the few X-ray structures of a bicyclic homodetic peptide 
determined at atomic resolution, the corresponding data statistics of which are given in Table 2. 
Overall, the structure of peptide 1b represents an assembly of two protomers being placed in the 
asymmetric unit as a homodimer. Both protomers adopt overall globular shape as predicted for 
bicyclic peptide scaffolds. The structure also unambiguously confirms the stereochemistry for 
the bridgehead residues as predicted by synthetic design. Crystal packing within the homodimer 
is governed predominantly by burying the hydrophobic residues of the two adjacent 1b 
protomers into a hydrophobic surface patch (Figure 2). 
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Table 2. Crystallographic data for 1b 
Space group P 21 21 21 
a, b, c (Å) 12.82   23.42  41.92 
, ,  (˚) 90 90 90 
Protomers/a.s.ua 2 
  
Data collection (XDS)  
Beamlines X06DA / X06SA 
Wavelength (Å) 0.73 
Resolution range (Å) 20.5 – 0.81 
(0.83-0.81) 
No. observations 135390 
No. unique reflections 12759 
Completeness (%)b 95.4 (64.7) 
Rmeas (%)b,c 7.3 (31.2)  
I/I2 21.1 (4.3) 
  
Refinement (Phenix)  
Resolution range (Å) 20.5 – 0.81 
No. reflections  12720  
No. reflections test set 636 
R/Rfree (%) 6.65 / 8.35 
No. atoms (without H)  
Peptide  336 
Additives 4 
Water 25 
B-factors (Å2)  
Overall  4.94 
Main Chain 2.25 
Solvent and Side chains 5.64 
a a.s.u., asymmetric unit. b The values in parentheses of resolution range, completeness, Rmeas and 
I/σ(I) correspond to the outermost resolution shell. c Rmeas / Rrim = hkl(N/N-1)1/2j |I(hkl; j) – 
‹I(hkl)›|/(hklj I(hkl;j)), where I(hkl;j) is the jth measurement of the intensity of the unique 
reflection (hkl) and ‹I(hkl)› is the mean over all symmetry-related measurements. 
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Figure 2. Stereoplot highlighting the hydrophobic interactions between the two protomers of 
bicyclic peptide 1b within the unit cell. Co-crystallized waters are shown as red spheres. Note 
the absence of water molecules around the phenyl rings. 
 
A stereochemical analysis of all residues of the two protomers reveals full agreement with 
most favorable regions in the Ramachandran plot. Accordingly, bond lengths, bond angles and 
dihedral angles are mostly consistent with parameter ranges of known peptide structures (Tables 
S1-S2). Moreover, secondary structure analysis reveals the presence of five intramolecular H-
bonds strongly stabilizing the overall backbone trace of peptide 1b. Among those, two involve 
hydrogen bond donor/acceptor pairs from the same peptide loop and define different β-turns. The 
one between εNH of D-Lys4 and CO of Glu8 defines a type II β-turn (φ9 = –58°, ψ9 = 140°, φ10 = 
83°, ψ10 = 5°), whereas the one between NH of D-Lys4 and CO of Ala1 defines a type I' β-turn 
(φ2 = 55°, ψ2 = 41°, φ3 = 74°, ψ3 = 1°). The remaining three hydrogen bonds, on the other hand, 
cross-link different loops of the bicyclic structure: they connect, respectively, NH of Ala1 to CO 
of Phe6, NH of Val5 to CO of Phe2 and NH of Phe6 to CO of Ala1, which is therefore a double 
hydrogen bond acceptor (Figure 3). 
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Figure 3. Stereoplot and 2D map of the crystal structure of 1b. Hydrogen bonds donor/acceptor 
pairs are connected by dashed lines. 2Fo–Fc electron density map of 1b contoured at 3.0 σ. 
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Conclusions 
 
We have reported the synthesis and crystal structure of a bicyclic homodetic peptide. The data 
show that for this macrobicyclic system the expected bridge configuration is indeed formed, as 
planned by the chirality of the branching amino acids. Furthermore, bicyclization only took place 
efficiently when bridgehead amino acid chiralities were properly matched. The stereoselective 
bridge formation opens the way for the planned synthesis of a large family of conformationally 
constrained bicyclic peptides, which constitute a promising new class of scaffolds for drug 
design. 
 
 
Experimental Section 
 
General. Fmoc-amino acids and reagents were purchased from commercial sources. Fmoc-Gly-
Wang resin (loading: 0.56 mmol/g) was purchased from Fluorochem UK. NMR data were 
acquired in DMSO-d6 at 298 K using a Bruker AvanceII 400 MHz NMR spectrometer. Proton 
resonances were assigned using TOCSY and HSQC data. Analytical RP-HPLC was performed 
with an Ultimate 3000 Rapid Separation LC using an Acclaim RSLC 120 C18 column (2.2 m, 
120 Å, 3×50 mm, flow 1.2 mL/min) from Dionex. Preparative RP-HPLC was performed with a 
Waters Prep LC Controller System using a Dr. Maisch GmbH Reprospher column (C18-DE, 
100×30 mm, particle size 5 µm, pore size 100 Å, flow 60 mL/min). The following eluents were 
used: A H2O/TFA (100:0.1); D H2O/MeCN/TFA (10:90:0.1). MS spectra were recorded on a 
Thermo Scientific LTQ OrbitrapXL. 
Solid phase synthesis. 400 mg of Fmoc-Gly-Wang resin were placed in a polypropylene syringe 
fitted with a polyethylene frit, a stopcock and a stopper. The resin was swollen in DCM for 15 
min. After removal of DCM, the Fmoc protecting group was removed. Stirring of the reaction 
mixture at any given step described below was performed by attaching the closed syringe to a 
rotating axis. Elongation of the peptide chain was performed using standard Fmoc-SPPS 
conditions. After the linear peptide chain was assembled, the polypropylene syringe was 
equipped with a septum and dried under vacuum for 1 hour. It was then swollen in dry DCM for 
15 min under argon. After removal of the solvent, Pd(PPh3)4 (0.1 eq) was diluted in 5 mL of dry 
DCM and added to the resin under argon. Phenylsilane (10 eq) was then added to the resin. The 
reaction was stirred under argon bubbling for 40 min. The reagents were removed by filtration 
and the resin washed with dry DCM. The resin was treated with sodium diethylthiocarbamate 
(20 mM in DMF, 5 mL) for 15 min to remove metal traces and finally washed with NMP, MeOH 
and DCM. The last Fmoc protecting group was removed with DMF/piperidine (4:1). 
On-resin cyclization. HATU (3 eq) and DIPEA (6 eq) were added to the deprotected peptidyl-
resin in 6 mL of NMP/DMSO (4:1) and the mixture was stirred at room temperature for 8 h. The 
reagents were removed by filtration and the resin washed with NMP, MeOH and DCM. 
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TFA cleavage and purification. The cleavage was carried out using a TFA/TIS/H2O (95:4:1) 
solution for 2 h. The peptide solution was separated from the resin by filtration, evaporated and 
dried under high vacuum and finally lyophilized from a freshly-prepared water/acetonitrile (4:1) 
solution. The lyophilized crude was then dissolved in a water/acetonitrile mixture, purified by 
preparative RP-HPLC and lyophilized again. Yields were calculated for the TFA salts of 1a and 
1a'. 
Second cyclization. 1b was synthesized by subjecting 1a to amide bond formation conditions in 
high dilution (0.7 mm). To a solution of PyBOP (3 eq) and DIEA (6 eq) in DCM/DMF (10:1), a 
10 mm solution of 1a in DMF was slowly added dropwise at 0 °C under stirring. The reaction 
was left stirring for 16 h at r.t. and monitored via RP-HPLC, until complete disappearance of the 
starting material. The reaction was then quenched by evaporation of the solvent. The crude was 
then dissolved in a water/acetonitrile mixture, purified by preparative RP-HPLC and lyophilized. 
The yield was calculated considering the trifluoroacetate salt of 1a as the starting material. 
X-ray diffraction experiments. The peptide was dissolved at 20 mg/mL in water and screened 
for suitable crystallization conditions using commercially available crystallization kits (Hampton 
Research; Aliso Viejo, CA, USA). Colorless rod-shaped crystals were obtained overnight by 
sitting drop vapor diffusion after mixing equal volumes of compound solution with 0.1 M 
sodium acetate trihydrate pH 4.6, 2.0 M ammonium sulphate at 18 °C. Diffraction data were 
collected at 100 K at the Swiss Light Source (Paul Scherrer Institute, Villigen) at beamlines 
X06DA and X06SA. Data processing, scaling and merging was performed by XDS and 
XSCALE19. The structure was determined by direct methods using SHELXD20. Structure 
refinement and model building was performed by iterative cycles of phenix.refine without 
imposing any stereochemical restrains in the last steps21 and Coot22. 
 
cyclo(Glu(Ala-Phe-Gly-lys-Val-Phe-Pro))-Ala-Gly-OH (1a, A1FGkVFPE1AG). Foamy white 
powder (67.5 mg, 60.4 µmol, 27%). Analytical RP-HPLC: r.t. = 1.765 min (A/D 100:0 to 0:100 
in 2.2 min, λ = 214 nm). MS (ESI+): C49H69N11O12 calc./obs. 1004.52/1004.52 [M+H]+, 
502.76/502.76 [M+2H]2+. 
cyclo(Glu(Ala-Phe-Gly-Lys-Val-Phe-Pro))-Ala-Gly-OH (1a', A1FGKVFPE1AG). Foamy 
white powder (43.8 mg, 39.2 µmol, 17%). Analytical RP-HPLC: r.t. = 1.704 min (A/D 100:0 to 
0:100 in 2.2 min, λ = 214 nm). MS (ESI+): C49H69N11O12 calc./obs. 1004.52/1004.52 [M+H]+, 
502.76/502.76 [M+2H]2+. 
cyclo(Ala1Phe2Gly3lys4Val5Phe6Pro7Glu8)cyclo(8α→4ε)Ala9Gly10 (1b, A1FGk2VFPE1AG2).  
Foamy white powder (22.8 mg, 23.1 µmol, 38%). Analytical RP-HPLC: r.t. = 3.91 min (A/D 
100:0 to 0:100 in 7.5 min, λ = 214 nm). MS (ESI+): C49H67N11O11 calc./obs. 986.51/986.51 
[M+H]+, 1008.49/1008.49 [M+Na]+. See supporting information for full 1H-NMR 
characterization. 
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